Microbot Medical (MBOT) Projected to Post Quarterly Earnings on Wednesday

Microbot Medical (NASDAQ:MBOT - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. On average, analysts expect Microbot Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Microbot Medical Price Performance

MBOT stock traded up $0.06 during midday trading on Monday, hitting $2.74. The company's stock had a trading volume of 1,442,912 shares, compared to its average volume of 2,244,055. Microbot Medical has a twelve month low of $0.82 and a twelve month high of $3.38. The company's fifty day moving average price is $2.05 and its 200 day moving average price is $1.65. The stock has a market capitalization of $95.20 million, a P/E ratio of -3.42 and a beta of 1.15.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research note on Thursday, April 10th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Microbot Medical stock. Goldman Sachs Group Inc. acquired a new position in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 37,744 shares of the biotechnology company's stock, valued at approximately $57,000. Goldman Sachs Group Inc. owned about 0.11% of Microbot Medical at the end of the most recent reporting period. Institutional investors own 16.30% of the company's stock.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.